Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $6.92 in the prior trading day, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) closed at $6.79, down -1.88%. In other words, the price has decreased by -$1.88 from its previous closing price. On the day, 1.68 million shares were traded. CRVS stock price reached its highest trading level at $7.0 during the session, while it also had its lowest trading level at $6.66.
Ratios:
Our goal is to gain a better understanding of CRVS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.29 and its Current Ratio is at 8.29. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on October 13, 2025, initiated with a Overweight rating and assigned the stock a target price of $16.
On January 02, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $11.
On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.Oppenheimer initiated its Outperform rating on August 18, 2023, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 27 ’25 when ORBIMED ADVISORS LLC sold 1,176,332 shares for $4.16 per share. The transaction valued at 4,891,894 led to the insider holds 7,165,006 shares of the business.
Thompson Peter A. sold 1,176,332 shares of CRVS for $4,891,894 on Jun 27 ’25. The Director now owns 7,165,006 shares after completing the transaction at $4.16 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRVS now has a Market Capitalization of 507089920 and an Enterprise Value of 442411904.
Stock Price History:
The Beta on a monthly basis for CRVS is 0.69, which has changed by 0.3057692 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, CRVS has reached a high of $9.60, while it has fallen to a 52-week low of $2.54. The 50-Day Moving Average of the stock is -15.43%, while the 200-Day Moving Average is calculated to be 22.04%.
Shares Statistics:
The stock has traded on average 1.29M shares per day over the past 3-months and 1513080 shares per day over the last 10 days, according to various share statistics. A total of 74.68M shares are outstanding, with a floating share count of 57.33M. Insiders hold about 23.24% of the company’s shares, while institutions hold 37.78% stake in the company. Shares short for CRVS as of 1765756800 were 9383518 with a Short Ratio of 7.29, compared to 1763078400 on 9902822. Therefore, it implies a Short% of Shares Outstanding of 9383518 and a Short% of Float of 15.890001000000002.
Earnings Estimates
The company has 4.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.13 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.15 and -$0.16 for the fiscal current year, implying an average EPS of -$0.16. EPS for the following year is -$0.58, with 4.0 analysts recommending between -$0.53 and -$0.63.
